Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #164726 on Biotech Values
DewDiligence
07/30/13 9:39 PM
#164728 RE: jq1234 #164726
03/23/15 10:33 AM
#188982 RE: jq1234 #164726
Pfizer Inc. and Eli Lilly and Company announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with their collaboration agreement. This announcement follows a decision by the U.S. Food and Drug Administration (FDA) to lift the partial clinical hold on the tanezumab development program after a review of a robust body of nonclinical data characterizing the sympathetic nervous system response to tanezumab. The data were submitted to the FDA in February 2015.